- Case report
- Open Access
Successful treatment of deep vein thrombosis caused by iliac vein compression syndrome with a single-dose direct oral anti-coagulant
Thrombosis Journalvolume 15, Article number: 4 (2017)
Although vein stenting is popular for treatment for venous thromboembolism due to mechanical compression, some cases are forced to avoid inserting align agents because of immunodeficiency.
An 82-year-old man with left extremity redness and swelling presented to a hospital for a medical evaluation. The patient was immunodeficient because of the adverse effects of his treatment for Castleman’s disease. A contrast-enhanced computed tomography scan revealed a venous thromboembolism in inferior vena cava and the left lower extremity. Magnetic resonance venography showed that the iliac artery was compressing the iliac vein. We were reluctant to place a stent in the iliac vein has because of the patient’s immunodeficient status. Three months of treatment using single-dose edoxaban (30 mg daily) resulted in complete resolution of the thrombus. This is the first report demonstrating that single-dose edoxaban without acute-phase parenteral anticoagulation is effective in the treatment of iliac vein compression.
A single-dose direct oral anti-coagulant without acute-phase parenteral anticoagulation is effective for mechanical compression
Vein stenting  is the generally accepted treatment for venous thromboembolism (VTE) due to mechanical compression, such as Paget-Schroetter syndrome and iliac vein compression syndrome (IVCS). However, in immunodeficient patients, this procedure may not be appropriate. We present a case of IVCS effectively treated only with a single-dose direct oral anticoagulant (DOAC) without acute-phase parenteral anticoagulation.
An 82-year-old, nonsmoking man with no history of VTE presented to an emergency department (ED) with a complaint of left lower extremity redness and swelling of 3 days duration. The patient had Castleman’s disease [2, 3], and was being treated with tocilizumab (Actemra™, Chugai Pharmaceutical Co., Ltd.) 370 mg per 3 weeks and predonisolone 4 mg daily . He was also taking acyclovir, voriconazole and sulfamethoxazole-trimethoprim (Baktar Combination Tablets™, Shionogi & Co., Ltd.) for immunodeficiency, a side effects of tocilizumab, in addition to clopidogrel 75 mg daily for a history of cerebral infarction. The serum D-dimer levels in the ED was 5.2 μg/mL, and VTE was suspected. A contrast-enhanced computed tomography (CT)-scan revealed prominent swelling in his left extremity and contrast deficits in the inferior vena cava (IVC) at the level of the lower lobe of kidney (Fig. 1a) and from the left external iliac vein (Fig. 1b) to the left superfacialis femoral vein. There was no evidence of pulmonary embolisms. The patient was diagnosed with VTE and admitted to our department. On admission, his blood pressure was 161/95 mmHg and his heart rate was 63 beats per minute. An arterial blood gas revealed an oxygen saturation (SaO2) of 95%. His body mass index was 23.0 kg/m2. Anticoaglation therapy, with a DOAC, edoxaban (Lixiana® and Savaysa®, Daiichi Sankyo, Inc.) 30 mg daily was initiated. An IVC filter was not inserted consistent with the latest guideline . Magnetic resonance venography demonstrated that the bifurcation of the left common iliac vein was compressed between the right common iliac artery and the fifth lumbar vertebral body (Fig. 2), confirming a diagnosis of IVCS. A hypercoagulability work-up revealed that protein C, protein S, antithrombin, and antiphospholipid antibodies were within normal limits. After 7 days, a follow-up contrast-enhanced CT scan showed a reduction in the size of the thrombosis (Fig. 3). The patient was permitted to discharge to home.
Anticoagulation therapy with edoxaban was continued for 3 months according to recent guidelines , and the VTE was reevaluated. A follow-up contrast-enhanced CT scan revealed that the thrombosis had completely resovled (Fig. 4). Moreover serum D-dimer concentration levels was negative. Edoxaban treatment was then discontinued according to a guideline , his clinical symptom, physical examination and D-dimer levels were monitored every month. The patient received treatment with no hemorrhagic complications during clinical course.
The patient gave his consent for the publication of this study.
In 1957, May R and Thurner J reported that 22% of 430 cadavers had stenosis of the left common iliac vein caused by compression of the right iliac artery, with wall thickening of the iliac vein and spur-like formation. The authors speculated that the compressions were due to chronic mechanical compression and out-forces from artery beats . In 1967, using venography, Cockett et al. reported that iliac vein compressions were observed in 65% of VTEs of the left iliac vein, and coined IVCS . In many cases, chronic iliac vein stenosis is asymptomatic because of the development of collateral branches in the pelvic cavity. The diagnosis is usually made when there is greater than 50% stenosis of the iliac vein ,or over 2 mmHg of pressure gradient in the vein . The first objective in the treatment of mechanical compression is release. Some studies have reported good results with iliac vein stenting for IVCS in both early and chronic phases [12, 13]. Stenting are generally performed overseas. In this case, consistent with the currrent literatures, we considered iliac vein stenting, but were reluctant the insert of align agents because of the patient’s immunodeficient status.
VTEs can result from a variety of causes. Inheritaed thrombophilia, malignant diseases [14, 15], mechanical compression from sleeping in a vehicle after an accident , lower limb operations [17, 18], and pregnancy are all important consideration in the differential diagnosis. In this case, thrombus formation was considered to be due to steroid administration, in addition to iliac compression, since steroid hormones have been shown to increase coagulation [19, 20].
In Japan, in addition to warfarin, apixaban , rivaroxaban  and edoxaban  are approved oral anti-coagulation agents for VTEs. The initial treatments for VTEs by apixaban and rivaroxaban requires higher doses, while edoxaban exerts its pharmacological effects at the same dose. Because the patient was at an increased risk of bleeding from the combined use of an anticoagulant with his antiplatelet drug, we selected edoxaban. A daily dose of 30 mg edoxaban was chosen because of his low body weight (less than 60 kg). Regimen of edoxaban in Hokusai-VTE study was an administration of edoxaban following acute-phase parenteral anticoagulation .
There is one report of successful treatment of IVCS with rivaroxaban (30 mg → 15 mg daily) . This case report adds to the literature by demonstrating that single-dose edoxaban (30 mg daily) without acute-phase parenteral anticoagulation is also effective though long-term follow-up is still required.
Although whether edoxaban treatment continuation or discontinuation was questionable, steroid therapy was already stopped, we judged that his VTE was reversible. However we monitored his clinical symptom, physical examination and D-dimer levels every month. A long term observation should be mandatory.
A use of single-dose DOAC is well known to be a treatment for VTE . To the best of our knowledge, this is the first report of successful treatment for IVCS with a single-dose DOAC without acute-phase parenteral anticoagulation.
Inferior vena cava
Iliac vein compression syndrome
Hokimoto S, Saito T, Oshima S, Ogawa H. Initial and mid-term outcomes of pulse infusion thrombolysis using a unique pump system and stent placement for deep vein thrombosis. Intern Med. 2008;47:1663–7.
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph‐node hyperplasia resembling thymoma. Cancer. 1956;9:822–30.
Chen KT. Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol. 1984;8:287–94.
Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol. 1982;128:1296–301.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest J. 2016;149:315–52.
Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, Origasa H, Satokawa H, Maeda H, Tanabe N. Current venous thromboembolism management and outcomes in Japan. Circ J. 2014;78:708–17.
Ando M, Fukuda I, Ito M, Kobayashi T, Masuda M, Miyahara Y, Nakanishi N, Niwa A, Ohgi S, Tajima H. Guidelines for the Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2009)-Digest Version. Circ J. 2011;75:1258–81.
May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology. 1957;8(5):419–27.
Cockett F, Thomas ML, Negus D. Iliac vein compression.--Its relation to iliofemoral thrombosis and the post-thrombotic syndrome. Br Med J. 1967;2:14.
Juhan C, Hartung O, Alimi Y, Barthélemy P, Valerio N, Portier F. Treatment of nonmalignant obstructive iliocaval lesions by stent placement: Mid-term results. Ann Vasc Surg. 2001;15:227–32.
Cockett F, Thomas ML. The iliac compression syndrome. Br J Surg. 1965;52:816–21.
Mickley V, Schwagierek R, Rilinger N, Görich J, Sunder-Plassmann L. Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation. J Vasc Surg. 1998;28:492–7.
Raju S, Neglen P. High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: a permissive role in pathogenicity. J Vasc Surg. 2006;44:136–44.
Sueta D, Hokimoto S. Onco-cardiology: Present and future. Int J Cardiol. 2016;215:38–40.
Sueta D, Tabata N, Akasaka T, Yamashita T, Ikemoto T, Hokimoto S. The dawn of a new era in onco-cardiology: The Kumamoto Classification. Int J Cardiol. 2016;220:837–41.
Sueta D, Akahoshi R, Okamura Y, Kojima S, Ikemoto, Yamamoto E. A Case of Venous Thromboembolism Due to Oral Contraceptive Intake and Spending Nights in a Vehicle. Intern Med. 2017;56:417–20.
Sueta D, Kaikita K, Okamoto N, Arima Y, Ishii M, Ito M, Oimatsu Y, Iwashita S, Takahashi A, Nakamura E. A novel quantitative assessment of whole blood thrombogenicity in patients treated with a non-vitamin K oral anticoagulant. Int J Cardiol. 2015;197:98–100.
Sueta D, Kaikita K, Okamoto N, Yamabe S, Ishii M, Arima Y, Ito M, Oimatsu Y, Iwashita S, Takahashi A. Efficacy Study of the COmbination of Edoxaban and Physiotherapy on the PRevention of Venous-Thromboembolism in patients after Total Knee Arthroplasty (ESCORT-TKA Trial): Study protocol for a randomized controlled trial. Clin Trials Regul Sci Cardiol. 2016;19:1–4.
Ozsoylu S, Strauss HS, Diamond LK: Effects of corticosteroids on coagulation of the blood. Nature. 1962;195:1214–15.
Sueta D, Kojima S, Izumiya Y, Yamamuro M, Kaikita K, Hokimoto S, Ogawa H. A Destabilized Case of Stable Effort Angina Pectoris Induced by Low-dose Adenosine Triphosphate. Intern Med. 2016;55:3291–4.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;2013:799–808.
Investigators EP. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;2012:1287–97.
Investigators H-V. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;2013:1406–15.
Koitabashi N, Niwamae N, Taguchi T, Ohyama Y, Takama N, Kurabayashi M. Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment. Thromb J. 2015;13:1.
We thank all of the paramedical staff and clinical secretaries for their kind support during this work.
Availability of data and materials
Please contact author for data requests.
All authors engaged in clinical practice. All authors read and approved the final manuscript.
The authors declare no conflicts of interest in association with the present study.
Consent for publication
The patient gave his consent for the publication of this study.
Ethics approval and consent to participate